Sarepta plans to seek full FDA approval for two therapies to treat Duchenne muscular dystrophy. The decision to pursue traditional approval comes despite the failure of a confirmatory trial, which had been a goal for the treatments. The move has been viewed positively by a Wall Street analyst, but some outlets suggest caution is still warranted.